Results 1-20 of 77 for drugs speaker:Denis Naughten

An Bille um an Aonú Leasú is Daichead ar an mBunreacht (An Comhaontú maidir le Cúirt Aontaithe um Paitinní), 2024: Céim an Choiste agus na Céimeanna a bheidh Fágtha - Forty-first Amendment of the Constitution (Agreement on a Unified Patent Court) Bill 2024: Committee and Remaining Stages (6 Mar 2024)

Denis Naughten: ...had a debate on rare diseases. Last Thursday, we had the Second Stage debate on this Bill, which was very timely. The provisions before us have huge implications for the development of orphan drugs, not just in this country but across Europe and globally. It is hoped that having a unified patent system in Europe will ensure more investment goes into the development of orphan drugs and...

Rare Diseases: Statements (6 Mar 2024)

Denis Naughten: I echo the comments by colleagues on access to drugs, expansion of the heel prick test and the implementation plan for rare diseases. It is one thing having a plan but having it implemented is something different. The surprising thing about rare diseases is that despite their name, they are collectively quite common, affecting at least one in 17 people in Ireland, equating to approximately...

Ceisteanna ó Cheannairí - Leaders' Questions (6 Mar 2024)

Denis Naughten: ...overstated. There has been an increase in demand for mental health services driven by the pandemic's exacerbation of mental health issues. One example is the increased prevalence of antipsychotic drug prescribing, which points to a deterioration in mental well-being particularly among younger and older people. We need an action plan which not only acknowledges the challenges post Covid...

An Bille um an Aonú Leasú is Daichead ar an mBunreacht (An Comhaontú maidir le Cúirt Aontaithe um Paitinní), 2024: An Dara Céim - Forty-first Amendment of the Constitution (Agreement on a Unified Patent Court) Bill 2024: Second Stage (29 Feb 2024)

Denis Naughten: ...states and has access to a single court to enforce that, rather than having to go to individual courts in different parts of Europe. At the moment if someone comes up with a novel idea, a new drug, a new piece of software or a new agricultural invention, they have to go country by country to get their patent registered. This, in particular, is a big barrier to small Irish companies...

Ceisteanna ó Cheannairí - Leaders' Questions (3 Oct 2023)

Denis Naughten: ...networks as well as the six remaining networks, we need to modernise our patient registers and establish electronic patient records. This will allow our patients to access the latest research and drug trials and assist in policy development. As the Taoiseach knows, the electronic health record programme has been paused until the new children's hospital health record programme is...

Written Answers — Department of Health: Medicinal Products (13 Jun 2023)

Denis Naughten: 1132. To ask the Minister for Health the reason melatonin is not covered by the medical card or the drug payment scheme; the plans he has, if any, to review this; and if he will make a statement on the matter. [27251/23]

Written Answers — Department of Health: Medicinal Products (25 May 2023)

Denis Naughten: 260. To ask the Minister for Health if he will approve the payment for low-dose naltrexone prescribed to long Covid patients under the drug payment scheme and the medical card scheme; and if he will make a statement on the matter. [25357/23]

Social Welfare Bill 2022: Committee and Remaining Stages (30 Nov 2022)

Denis Naughten: ...fit woman, a specialist clinical physiotherapist, who has gone to a plethora of private clinics, which she has paid for, and now has a monthly bill for medication of €270, which is not covered under the General Medical Services, GMS, or the drug refund scheme. She is receiving zilch from the State, even though she worked right the way through the pandemic. Because she ended up...

COP27: Statements (29 Nov 2022)

Denis Naughten: ...diseases who are living in fuel poverty, such individuals end up attending their GPs and emergency departments less frequently, require less use of hospital services and use fewer prescribed drugs. This is a win for climate, a win for health services and a win for the people with these chronic illnesses. If we are to capitalise on that, we need to invest in the retrofitting of homes of...

Ceisteanna ó Cheannairí - Leaders' Questions (24 Nov 2022)

Denis Naughten: ...of Hygiene and Tropical Medicine. The empirical evidence shows that, among other things, there was a reduced usage of GP, emergency department and hospital services and a reduced volume of prescribed drugs - a win for our climate, a win for our health services and, most important, a win for people with chronic conditions, such as asthma and COPD. Yet there is no targeted investment in...

Mother and Baby Institutions Payment Scheme Bill 2022: Second Stage (Resumed) (27 Oct 2022)

Denis Naughten: ...Professor Meenan had conducted vaccine trials without the authorisation of the then Minister, yet nothing was done. When it comes to mother and baby homes, it was not just the State but reputable drug companies, academics and even academic journals such as the British Medical Journaland The Lancetthat were all prepared to turn a blind eye to the basic human rights of these children,...

Written Answers — Department of Health: Medicinal Products (14 Sep 2022)

Denis Naughten: 469. To ask the Minister for Health further to Parliamentary Question No. 258 of 11 May 2022, when the HSE will approve the reimbursement under the high-tech drug arrangements for kaftrio for children under 12 years of age; the reason for the delay in approval in view of the fact that it has already been approved for children aged 12 years and over; the steps taken by the HSE to consider this...

Written Answers — Department of Health: Medicinal Products (14 Jul 2022)

Denis Naughten: 709. To ask the Minister for Health if he will offer immunocompromised & vulnerable patients access to a drug (details supplied); and if he will make a statement on the matter. [38973/22]

Written Answers — Department of Health: Medicinal Products (30 Jun 2022)

Denis Naughten: ...for Health the steps that are being taken to increase the volume of generic medicines used to fulfil prescriptions to achieve the European Union average of 70%; the estimated savings to the annual drug bill as a result; and if he will make a statement on the matter. [35122/22]

Strike Action by the Medical Laboratory Scientists Association: Motion [Private Members] (25 May 2022)

Denis Naughten: ..., we are frequently contacted by patients or their families about the latest medicine for a specific illness that can transform the life of a patient. They are looking for approval under the drug reimbursement scheme. This is all part of the rapidly expanding area of healthcare known as personalised medicine. This means that medical care is based on the patients' own genes and specific...

Written Answers — Department of Health: Medicinal Products (11 May 2022)

Denis Naughten: 258. To ask the Minister for Health when the HSE will approve the reimbursement under the high-tech drug arrangements for kaftrio for children under 12 years of age; the reason for the delay in approval in view of the fact that it has already been approved for children aged 12 years and over; the date when the applicant company submitted a rapid review dossier of evidence to the HSE; the...

Written Answers — Department of Health: Medicinal Products (7 Apr 2022)

Denis Naughten: 398. To ask the Minister for Health when a report (details supplied) on the drug reimbursement process will be published; the date it was submitted to his Department; and if he will make a statement on the matter. [19023/22]

Health Insurance (Amendment) Bill 2021: Committee and Remaining Stages (8 Dec 2021)

Denis Naughten: ...and substitute the following: “but does not include a claim— (i) under a policy that fails to provide cover for day case and inpatient care in model 2 hospitals, or (ii) for the cost of drugs that are not listed on the Reimbursement List established and published by the Health Service Executive under section 17 of the Health (Pricing and Supply of Medical Goods) Act...

Written Answers — Department of Health: Medicinal Products (21 Sep 2021)

Denis Naughten: 527. To ask the Minister for Health when he expects a decision on the approval of a drug (details supplied); and if he will make a statement on the matter. [44474/21]

Written Answers — Department of Health: Medicinal Products (15 Jul 2021)

Denis Naughten: 356. To ask the Minister for Health when he expects a decision on the approval of a drug (details supplied); and if he will make a statement on the matter. [32184/21]